Novel (E)-3-(1-substituted-1H-indazol-5-yl)-N-hydroxypropenamides as histone deacetylase inhibitors: design, synthesis and structure–activity relationships

Two series of N -hydroxybenzamides showed excellent HDAC inhibition and cytotoxicity against three human cancer cell lines, including SW620, PC3, and MDA-MB-231.